文献速递妇科

淋巴结阳性宫颈癌术后化疗:多中心II期临床试验(JGOG1067)结果

Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
PubMed 文献 · Gynecol Oncol · 2018-04-13

日本妇科肿瘤组多中心II期研究(JGOG1067)评估IB-IIA期鳞状宫颈癌根治性子宫切除术后盆腔淋巴结阳性患者接受伊立替康联合奈达铂术后化疗的疗效与安全性,主要终点2年无复发生存率为87.1%,5年总生存率为86.5%,仅9.7%患者出现下肢淋巴水肿。

要点

  • 62例淋巴结阳性宫颈癌患者术后接受伊立替康联合奈达铂化疗,55例(88.7%)完成5个周期。
  • 2年无复发生存率87.1%(95%CI 75.9-99.3),5年无复发生存率77.2%(95%CI 64.5-85.8)。
  • 5年总生存率86.5%(95%CI 74.8-93.0),14例(22.5%)复发,其中8例死于疾病。

核心结论

  • 术后化疗不放疗在淋巴结阳性宫颈癌高危患者中非常有效。

研究设计与样本

  • 日本妇科肿瘤组多中心II期研究(JGOG1067),纳入根治性子宫切除术后确认盆腔淋巴结转移的IB-IIA期鳞状宫颈癌患者,共62例进行分析。

主要发现

  • 55例(88.7%)完成5个周期计划治疗,中位随访66.1个月(范围16.8-96.6个月)。
  • 2年无复发生存率87.1%(95%CI 75.9-99.3),5年无复发生存率77.2%(95%CI 64.5-85.8)。
  • 14例(22.5%)随访期间复发,其中8例死于疾病,5年总生存率86.5%(95%CI 74.8-93.0)。
  • 仅9.7%患者出现下肢淋巴水肿。

关键数值与推荐

  • 术后接受伊立替康(CPT-11)60mg/m2静脉注射第1天和第8天,奈达铂(NDP)80mg/m2静脉注射第1天。
  • 化疗于术后6周内开始,每28天重复一次,最多5个周期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This multicenter phase II Japanese Gynecologic Oncology Group study (JGOG1067) was designed to evaluate the efficacy and safety of postoperative chemotherapy in patients with node-positive cervical cancer. METHODS: Patients with stage IB-IIA squamous cervical cancer who underwent radical hysterectomy and were confirmed to have pelvic lymph node metastasis were eligible for this study. The patients postoperatively received irinotecan (CPT-11; 60mg/m2 intravenously on days 1 and 8) and nedaplatin (NDP; 80mg/m2 intravenously on day 1). Chemotherapy administration commenced within 6weeks after surgery and was repeated every 28days for up to 5cycles. The primary endpoint of this study was the 2-year recurrence-free survival (RFS) rate. The secondary endpoints were the 5-year overall survival (OS) rate, 5-year RFS rate, and adverse events such as complications of chemotherapy and lower-limb edema. RESULTS: Sixty-two patients were analyzed according to our protocol, among whom 55 (88.7%) completed 5cycles of scheduled treatment. The median follow-up period was 66.1months (range, 16.8-96.6months). The 2-year and 5-year RFS rates were 87.1% (95% confidence interval [CI]: 75.9-99.3) and 77.2% (95% CI: 64.5-85.8), respectively. Fourteen patients (22.5%) experienced recurrence during the follow-up period, 8 of whom died of the disease. The 5-year OS rate in this study was 86.5% (95% CI: 74.8-93.0). Only 9.7% of the patients experienced lymphedema in their legs. CONCLUSION: Postoperative chemotherapy without radiotherapy was found to be very effective in high-risk patients with node-positive cervical cancer.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Matoda M, Takeshima N, Michimae H, et al. Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067). Gynecol Oncol. 2018. PMID: 29661497. doi:10.1016/j.ygyno.2018.04.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。